Drug General Information
Drug ID
Former ID
Drug Name
EGFR antisense DNA
Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh
Drug Type
Antisense drug
Indication Head and neck cancer [ICD-11: 2D42] Phase 1/2 [1]
University of Pittsburgh
Target and Pathway
Target(s) EGFR messenger RNA (EGFR mRNA) Target Info . [2]
REF 1 ClinicalTrials.gov (NCT00903461) Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma. U.S. National Institutes of Health.
REF 2 Antitumor Effects of EGFR Antisense Guanidine-Based Peptide Nucleic Acids in Cancer Models. ACS Chem Biol. 2013 February 15; 8(2): 345-352.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.